{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tyrosine
to a specific field?
Status:
US Approved Rx
(2019)
Source:
BLA761073
(2019)
Source URL:
First approved in 1998
Source:
BLA103792
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2007)
First approved in 1992
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
ANDA212416
(2021)
Source URL:
First approved in 1975
Source:
CALCIMAR by SANOFI AVENTIS US
Source URL:
Class:
PROTEIN
Conditions:
Calcitonin-salmon is a polypeptide hormone secreted by the parafollicular cells of the ultimobranchial gland of salmon fish. Calcitonin-salmon Nasal Spray is a polypeptide of 32 amino acids manufactured by recombinant DNA technology and is identical to calcitonin produced by salmon fish or chemical synthesis. Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts. Single injections of calcitonin cause a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In vitro studies have shown that calcitonin-salmon causes inhibition of osteoclast function with loss of the ruffled osteoclast border responsible for resorption of bone. Calcitonin-salmon Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females.
Status:
Investigational
Source:
INN:anbenitamab repodatecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:caxmotabart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:nesfrotamig [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lasrekibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vebanvibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:albipagrastim alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:caxmotabart entudotin [INN]
Source URL:
Class:
PROTEIN
